Virtu Financial LLC Acquires New Stake in Disc Medicine, Inc. (NASDAQ:IRON)

Virtu Financial LLC purchased a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 4,875 shares of the company's stock, valued at approximately $309,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock worth $23,333,000 after purchasing an additional 70,983 shares during the last quarter. State Street Corp grew its position in shares of Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company's stock worth $40,683,000 after buying an additional 235,115 shares in the last quarter. Verition Fund Management LLC acquired a new stake in Disc Medicine in the third quarter valued at $589,000. Charles Schwab Investment Management Inc. boosted its stake in Disc Medicine by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company's stock valued at $7,890,000 after acquiring an additional 19,401 shares during the last quarter. Finally, Barclays PLC boosted its stake in Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company's stock valued at $1,972,000 after acquiring an additional 22,202 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Scotiabank upped their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Cantor Fitzgerald increased their target price on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. TD Cowen started coverage on Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating for the company. Finally, Wedbush reissued an "outperform" rating and set a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of "Buy" and an average target price of $93.80.

Remove Ads

Disc Medicine Stock Down 5.0 %

NASDAQ IRON traded down $2.49 during trading hours on Tuesday, hitting $47.15. The company had a trading volume of 696,037 shares, compared to its average volume of 343,657. The firm has a market cap of $1.63 billion, a P/E ratio of -11.85 and a beta of 0.73. Disc Medicine, Inc. has a fifty-two week low of $25.64 and a fifty-two week high of $68.73. The business has a fifty day simple moving average of $54.20 and a 200-day simple moving average of $56.21.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. Equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In related news, CFO Jean M. Franchi sold 3,136 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,162.88. Following the completion of the transaction, the chief financial officer now directly owns 69,530 shares of the company's stock, valued at $3,794,947.40. This represents a 4.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total value of $470,625.00. Following the sale, the insider now directly owns 14,035 shares in the company, valued at $880,696.25. The trade was a 34.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 369,190 shares of company stock worth $20,118,719. 4.24% of the stock is owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.